Small molecule · Inhibitor of neutrophil elastase (ELANE) · developed by Mereo BioPharma
Alvelestat is an orally bioavailable, selective and reversible inhibitor of human neutrophil elastase, a serine protease released by neutrophils during inflammation. It is being studied in lung diseases such as chronic obstructive pulmonary disease, emphysema and alpha-1 antitrypsin deficiency.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03986086 | Phase 1/2 | Hematologic Malignancy | Withdrawn | MREO |
| NCT04539795 | Phase 1/2 | Covid19 | Completed | MREO |
| NCT03679598 | Phase 2 | Alpha-1 Antitrypsin Deficiency (AATD) | Completed | MREO |
| NCT03636347 | Phase 2 | Alpha 1-Antitrypsin Deficiency | Completed | MREO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alpha 1-Antitrypsin DeficiencyAlpha-1 Antitrypsin Deficiency (AATD)COPDCovid19EmphysemaEmphysema or COPDHematologic Malignancy
Updated Oct 25, 2026. Something wrong or missing? Report it on the MREO page.
See MREO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MREO catalysts and pipeline →